IDIBELL on the media
IDIBELL celebrates 15 years
The Bellvitge Biomedical Research Institute commemorates its 15 years of existence evaluating its past and facing the future with optimism
Raúl Zamora wins the 2nd edition of the Jesús Serra Foundation Research Awards
The researcher Raúl Zamora Ros, from the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan Institute of Oncology (ICO), has been chosen by the jury of the Jesús Serra Foundation Research Awards as the winner in the clinical research category. This award is aimed at scientists below 45 years old specialized in nutrition, food and […]
Fluorescent dopaminergic neurons to accelerate Parkinson’s disease research
A team of scientists led by Dr. Antonella Consiglio from the IDIBELL and the University of Barcelona (UB), and Dr. Angel Raya from the Center of Regenerative Medicine of Barcelona (CMR[B]/IDIBELL) reveal in Scientific Reports today an efficient and new method for generating fluorescently-labeled dopaminergic neurons (DAn), a specific cell type that die in Parkinson’s […]
The new Program for Regenerative Medicine in Catalonia has officially launched
IDIBELL and CMR[B] join efforts for the new Clinical Translational Program for Regenerative Medicine in Catalonia (P-CMR[C]), presented in an event chaired by the president of the Generalitat
IDIBELL – ICO researchers set new bases to develop therapies against colorectal cancer
The discovery is based on targeting the tissue surrounding the tumor, instead of the tumor directly
The PhD day showcases the talent of young researchers of Bellvitge
Last Thursday, April 11, another edition of IDIBELL PhD day took place in IDIBELL in the Duran i Reynals Hospital. This scientific symposium, framed in the project of specialization and territorial competitivity IN’H – L’Hospitalet, ecosistema innovador de salut of the Hospitalet City Council, is organized by the predoctoral researchers of the Bellvitge Campus and […]
New muscular disease: Myoglobinopathy
An international collaboration led by IDIBELL identifies the first disease caused by a mutation in myoglobin
Collaboration between health institutions and industry creates value for the patient
Innovation is the key to achieve transformation and sustainability in the health system
Scientists confirm the validity of current techniques for predicting resistance to treatment in metastatic colorectal cancer
Researchers from IDIBELL and ICO show that current mutational analysis techniques are sufficiently sensitive to predict resistance to treatment with EGFR inhibitors in metastatic colorectal cancer
